DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Lastacaft is a drug marketed by Allergan and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has forty-six patent family members in thirty countries.
The generic ingredient in LASTACAFT is alcaftadine. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the alcaftadine profile page.
Lastacaft was eligible for patent challenges on July 28, 2014.
By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 19, 2027. This may change due to patent challenges or generic licensing.
There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for LASTACAFT
|Suppliers / Packagers:||1|
|Bulk Api Vendors:||47|
|Drug Prices:||Drug price information for LASTACAFT|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for LASTACAFT|
|DailyMed Link:||LASTACAFT at DailyMed|
Generic Entry Opportunity Date for LASTACAFT
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for LASTACAFT
Identify potential brand extensions & 505(b)(2) entrants
|ORA, Inc.||Phase 4|
|Starx Research Center, LLC||Phase 4|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Allergan||LASTACAFT||alcaftadine||SOLUTION/DROPS;OPHTHALMIC||022134-001||Jul 28, 2010||RX||Yes||Yes||Start Trial||Start Trial||Start Trial|
|Allergan||LASTACAFT||alcaftadine||SOLUTION/DROPS;OPHTHALMIC||022134-001||Jul 28, 2010||RX||Yes||Yes||Start Trial||Start Trial||Y||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Patent No.||Patent Expiration|
|Allergan||LASTACAFT||alcaftadine||SOLUTION/DROPS;OPHTHALMIC||022134-001||Jul 28, 2010||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>Patent No.||>Patent Expiration|